The United European Gastroenterology (UEG) week is taking place from the 19th to the 23rd October in Barcelona, and the New Deal project team will attend it! We will hold a Common Interest Group meeting called “Unmet therapeutic needs in IBD – how new targeted medicine could help” the 22nd of October at 18:00h.
Recent therapeutic development programs in the field of Inflammatory Bowel Diseases, particularly JAK inhibitors or S1PR modulators have shown to face systemic toxicity issues, thus compromising their efficacy and highlighting the urge to find alternative targeted solutions.
Since their first FDA approval in 2018, small interfering RNAs have turned into great candidates to meet this objective, opening the way for this new type of therapeutics for a large range of applications from viral disease to cancer and IBD.
In this context, to help these powerful molecules reach their target nanostructured lipid carriers have stand out as ideal tools to improve the targeted and local delivery into inflamed gut.
For these reasons, in this meeting experts from the multidisciplinary team at New Deal will discuss the potential of this targeted therapy. The session will be conducted by Julian Panés (Chief of the Department of Gastroenterology at Hospital Clínic Barcelona), Fabrice Navarro (New Deal project coordinator and Head of the Microfluidic Systems and Bioengineering Laboratory at CEA, Grenoble) and Xavier Gidrol (Head of Biomics Laboratory CEA, Grenoble).
If you are attending the UEG week, don’t hesitate to come to our reunion! It would be a great chance to discuss with us about the role that targeted medicine could play in the future of IBD treatments